Delivery Order SPE2DB20D9214-SPE2DB25FD4WN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,792.31 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location with completion expected by July 24, 2025. This delivery order was awarded without a set-aside designation, allowing the vendor to compete in the open...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 80 mg tablets. This delivery order is part of a larger single-award indefinite delivery contract (IDC) between the DLA and DMS Pharmaceutical Group, valued up to $499,999,999, that runs through December 31, 2025. The IDC...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, a prescription oncology medication. This firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The order will be fulfilled and delivered to Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its operations as a woman-owned small business pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a $4,169.59 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order is for the supply of 4,566,561,052 units of the prescription drug Xtandi 40 mg tablet, with a completion date of November 27, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The place of performance is located in Park Ridge, Illinois, where the vendor...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of the drug Xtandi 80 mg tablets and has an ultimate completion date of August 27, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,169.59 contract is for the delivery of Xtandi 80 mg tablets. This order is part of a larger $499,999,999 indefinite delivery contract (IDC) with DMS Pharmaceutical Group to provide a comprehensive range of pharmaceutical items, including branded and generic prescription drugs,...
- This is a $4,169.59 firm fixed-price delivery order awarded by the Defense Logistics Agency's Medical Supply Chain group to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The order is for 120 tablets of the prescription drug Xtandi 40mg, with an ultimate completion date of March 20, 2024. DMS Pharmaceutical Group holds a broader indefinite delivery contract (SPE2DB) with the Defense Logistics Agency valued at up to $4,999,999 through 2025, which...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB25FD4WNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, which became effective on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its facility in Park Ridge, IL. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The IDC serves as a primary vehicle for the DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. Xtandi, an oncology treatment medication, represents one of the specialized pharmaceutical products available through this contract framework that enables efficient distribution of critical medications to military health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 7/23/25 |